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Multiple myeloma (MM) is a “clonal” plasma cell malignancy that produces monoclonal protein as opposed to the polyclonal gamt
mopathy seen in inflammatory diseases. MM usually 
evolves from a premalignant monoclonal gammopathy 
of undetermined significance (MGUS). MGUS is also 
a clonal plasma cell proliferation that is asymptomatic. It 
can stabilize, decrease or even disappear, but it also can 
progress insidiously to myeloma or related malignancy 
at a rate of 1% per year.1 In the United States, MM is 
the second most common hematologic malignancy next 
to lymphoma.2 The disease is less common in whites 
as compared with blacks.2 The incidence in Taiwan is 
much less than in whites.3 The etiology of MM is unt
known. In most MM cases, somatic hypermutation in 
IgH and Igk/Igl functional rearrangements and chart
acteristic translocations targeting the switch regions of 
IgH are noted.4 Milestones in MM biological research 
are linked to the discovery of interleukin 6 (ILt6) as a 
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multiple myeloma is a clonal plasma cell dyscrasia with clinical heterogeneity. as of now, two key ques-
tions need to be answered before starting to treat a newly diagnosed myeloma patient. one is whether 
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of patients may not respond well to high-dose chemotherapy and require early introduction of newer 
treatments such as the bortezomib-containing regimen. the main factor in determining the eligibility for 
stem cell transplants is age. based on the current literature and situation in taiwan, we suggest stem cell 
transplantation if the patient is younger than 55 years of age. each case should be considered individu-
ally if the age of the patient is between 55 and 70 years. finally, we have also reviewed the status and 
the treatment of multiple myeloma in taiwan. fortunately, there has been an improvement in awareness, 
diagnosis and treatment. cytogenetic studies have been applied in risk evaluations, but are limited in a 
few centers due to lack of availability. With the exception of the agent lenalidomide, new novel agents are 
available for treating of myeloma in taiwan.
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myeloma growth factor and survival factor5,6 and to the 
recognition of stromal cell dependence.7
History of therapeutic improvement in multiple my-
eloma
The current treatment of MM has significantly imt
proved. We have seen a revolution in the availability 
of novel agents for MM for which therapeutic agents 
had been scarce. In a recent analysis of 2981 newly dit
agnosed MM cases, those diagnosed in last decade had 
a 50% improvement in overall survival (OS) ( 44.8 vs 
29.9 months, P<.001).8 Treatment started in 1844 
with rhubarb pill and infusion of orange peel (Figure 
1).9 There were no definite benefits to treatment unt
til 1958 when Blokhin et al used sacolysin (melphat
lan).10,11 Corticosteroids were then tested in 1962 by 
Maas.12 Experience with the regimen of melphalan plus 
prednisone was published in 1969 by Alexanian et al.13 
With an overall response (OR) rate of 53%, this was 
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a standard treatment for 40 years. The M2 protocol 
(carmustine, cyclophosphamide, melphalan, vincristine 
and prednisone) was introduced in 1974 by Harley et 
al.14,15 McElwain and Poweles reported the first autolot
gous bone marrow transplant in 1983.16 This treatment 
later played a major role in MM therapy.17 In 1984, ext
perience with the VAD (vicristine, adriamycine and 
dexamethasone) regimen, in which it was used first to 
treat refractory dieases after alkylating agents,18 was 
first published. It was then used in the preparation of 
autologous transplant19 to avoid stem cell damage by 
alkylators.20 Despite these improvements, MM is still 
not curable. The OS is short (29 months for advanced 
stage).21 Therefore, effort is needed to improve survivt
al.
New medications for multiple myeloma
Thalidomide
Thalidomide was used as a sedative and antiemetic for 
emesis gravidarum in 1957. It was withdrawn from the 
market in 1961 due to teratogenic malformation.22 In 
1994, it was found to have antiangiogenetic propert
ties.23 Furthermore it exerted immunomodulatory and 
antitinflammatory properties. In 1999, Barlogie et al 
tried thalidomide on 84 patients with relapsed or ret
fractory MM and found a 32% OR rate, including a 2% 
complete response (CR) rate.24 In the United States, 
the Food and Drug Administration (FDA) approved 
its use in MM in 2006 after more data became availt
able.25 
Bortezomib (PS-341)
Bortezomib, a boronic acid dipeptide, is a proteosome 
inhibitor.26 The ubiquitintproteosome pathway is ret
sponsible for multicatalytic degradation of eukaryocytic 
cellular proteins.27 Bortezomib inhibits this pathway, 
leading to cellular apoptosis, with malignant, transt
formed, and proliferating cells being more susceptible. 
Von Meltzer et al also showed that it inhibits human ost
teoclast differentiation, activation and resorptional activt
ity in a doset and timetdependent manner.28,29 Following 
a successful phase 1/2 trial,29,30 the randomized phase 
3 APEX trial compared bortezomib with a high dose 
of dexamethasone in 669 patients with relapsed and 
relapsed/refractory MM. The bortezomib group had a 
better OR, median time to progression and OS.31 The 
FDA approved its use in MM in 2003. It was also tried 
in combination with dexamethasone as induction treatt
ment in a phase 2 study by Harousseau et al prior to 
ASCT.32 This regimen was compared to VAD as well. 
The result showed better OR, CR and very good partial 
response (VGPR) both before and after transplant.33 
Longer followtup is needed to demonstrate any benefit 
in progressiontfree survival (PFS) and OS. Other studt
ies revealed that it had a similar effect in hightrisk pat
tients34,35 and was tolerated in elderly patients.34
Lenalidomide (CC-5013)
Lenalidomide is an immunomodulatory analog of that
lidomide with an improved safety profile.36 Richardson 
et al conducted a multicenter randomized phase 2 trial 
and showed that the OR was 25% by single agent (24% 
for 30 mg daily and 29 % for 15 mg bid).37 It was apt
proved by the FDA for treatment of MM in 2006 after 
two large phase 3 trials.38,39 
Bisphosphonates
Bisphophonates are not new drugs, but they could have 
new application for MM treatment. They have been used 
for hypocalcemia and bone lesions secondary to maligt
nancy.40 Emerging evidence suggests that they may have 
antitumor properties.41 The new generation of bisphost
phonates (pamidronate and zoledronic acid) exert an ant
timyeloma effect indirectly by inducing osteoclast apopt
tosis, thus reducing a major source of antiapoptotic ILt6 
molecule,42 or directly by inducing myeloma cell apopt
tosis.43 Zoledronic acid also demonstrated inhibition of 
angiogenesis,44 invasion and adhesion of tumor cells and 
overall tumor progression.45 Aviles et al conducted a cont
Figure 1. Timeline of the treatment history of multiple myeloma.
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trolled clinical trial of zoledronic acid in MM used after 
treatment with cyclophosphamide, vincristine, melphat
lan and prednisone.46 After chemoteraphy, patients were 
randomized to either zoledronic acid or no zoledronic 
acid. Zoledronic acid not only prevented skeletal events, 
but there was also improved eventtfree survival (EFS) 
and OS. A phase 2 study is being carried out on Asian 
MM patients.47 The regimen consists of lowtdose dexat
methasone, thalidomide and hightfrequency zoledronic 
acid (dtZ). Preliminary results suggest dtZ is able to int
duce a very good OR (>90%) and a very high CR or very 
good partial response rate of 50% (VGPR, defined as 
≥90% reduction in serum M protein). These encouragt
ing early results have led to a further larger trial.48
How to characterize the high-risk patients with mul-
tiple myeloma
It is clear that the clinical heterogeneity of MM is estabt
lished. As novel therapeutics have emerged, it is increast
ingly important to introduce a risktadapted approach 
against MM.49 Therefore, the correct identification of 
patients at high risk of early death is very important 
in establishing proper treatment. Many studies have 
shown that several genetic categories exist, defining subt
sets of MM with dissimilar outcomes and responses to 
therapy.50,51 Gene profiling, which is under study,52 could 
become a powerful tool to identify the hightrisk subt
groups,53 but it is complex to apply widely in daily pract
tice. At present, genetic studies by conventional banding 
technique or fluorescent in situ hybridization (FISH) 
and good clinical staging are the best available ways to 
characterize hightrisk patients. Plasma cell labeling may 
help, but is not commonly used.
Staging in multiple myeloma
Higher clinical staging usually means a poor prognot
sis. In 1975, Durie and Salmon had developed a stagt
Table 1. Criteria for new international Staging System (iSS) and median survival: comparison to durie-Salmon (dS) Staging System.
   ISS Serum b2-microglobulin (mg/L) Serum albumin (g/dL) Median survival (months)
a DS    
   i <3.5 ≥3.5 62 (62) ia
(58) iia
   ii <3.5 <3.5 44 (45) iiia  
>3.5 to <5.5 any
   iii >5.5 any 29 (22) iB
(34) iiB
(24) iiiB
aThe number in parentheses is the median survival for the dS system.
ing system based on creatinine (A or B), the degree of 
anemia, paraprotein, and bone lesions with the presence 
of hypercalcemia (stages 1t3).54 Other staging systems 
were developed,55,56 but the easiest and most effective 
one was the International Staging System (ISS)”. ISS 
was designed by Greipp et al in 2005.21 It was based on 
univariate and multivariate analyses and three types of 
modeling approaches. Serum b2tmicroglobulin (b2M) 
and serum albumin were selected from the various pot
tential prognostic factors both because of the statistical 
power in various models as well as the widely known 
availability of these two simple inexpensive tests.21,57 The 
survival differences were reproducibly demonstrated in 
the test and validation datasets (Table 1). The broad apt
plicability of the ISS system was further illustrated with 
validation by geographic area, patient age, and treatment 
type and in comparison with DurietSalmon staging 
system.21 Of particular note, ISS stage 3 is clearly delint
eated as a poortrisk group (39% of patients), with a met
dian survival time of 29 months. This is most helpful in 
developing countries where cytogenetic study is limited. 
Why are b2M and serum albumin such powerful progt
nostic factors? b2M reflects not only tumor mass and 
renal function, but also yet unknown parameters, post
sibly including immune function.21 The specific cause of 
decreased albumin in some MM patients is not certain; 
however, a lower albumin may reflect effects on the liver 
by ILt6 produced by the microenvironment of myeloma 
cells.21 The strong correlations between serum levels of 
Sb2M and albumin and MM survival imply connections 
to important underlying mechanisms.
Cytogenetic studies and fISH in multiple myeloma
Conventional cytogenetics by karyotyping has emerged 
as a relevant prognostic factor in MM patients. Deletion 
of chromosome 13(del13) is the most common and the 
most significant prognostic abnormality observed.58t60 
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Hypodiploidy is another change detected by this metht
od and indicates poor prognosis as well. This convent
tional banding is able to identify abnormalities in the 
myeloma clone in 20% to 30 % of patients. FISH techt
niques may offer more sensitive and specific identificat
tion of critical abnormalities including del17 pt, t(4;14) 
and t(14;16). These changes constitute hightrisk get
netic categories.49t51 The consistency in the prognostic 
value of cytogenetics has been incorporated into routine 
clinical practice in some centers such as at Mayo Clinic. 
Although prognostically important correlations have 
emerged, practical application of these techniques have 
been hampered by lack of standardization, costs, and 
restricted availability.
Current approach for newly diagnosed multiple my-
eloma
The two most important factors in deciding MM treatt
ment are risk adaptation and whether the patient is a 
transplant candidate. The former has been discussed 
above. Now we are discussing the principle of transt
plantation. The role of hightdose therapy (HDT)/ 
autologous stem cell transplant (ASCT) is controt
versial at present. IFM (Intergroupe Francophone du 
Myelome) was the first to demonstrate in a randomized 
trial the superiority of HDT/ASCT by using marrow 
stem cells.61 On the contrary, Barlogie et al did not show 
superiority in the US Intergroup trial (S9321).62 The 
7tyear OS was 37% (HDT) vs 42% ( without HDT). 
The rapid hematopoietic recovery by mobilized peripht
eral blood stem cells (PBSC) transplant was confirmed 
in the IFM 94 trial and so was its efficacy.63 Therefore, 
HDT in MM treatment now refers to ASCT by PBSC 
for rescue. As pointed out by both Blade and Visole 
there was a significant improvement statistically in OS 
on an intentttottreat basis in younger patients who ret
ceived HDT. The benefit over conventional therapy was 
15 months.64 The major key for eligibility of ASCT is 
age. Other important factors are performance, comort
bidities and patient choice. Indeed, in most reports of 
phase 2 studies of HDT, the median patient age did 
not exceed 52 years.65,66 In addition, the benefits from 
HDT studies were only seen in patients less than 60 
years of age.61,67 Fermand et al studied the impact of 
HDT in MM patients between the ages of 55 and 65 
years. With a median followtup time of approximately 
10 years, this randomized trial confirmed a benefit of 
HDT in terms of EFS and time without symptoms, 
treatment, and treatment toxicity (TwiSTT), but not 
the OS.68 Therefore, we recommend individualizing in 
the age group between 55t70 years before the decision 
on HDT. Other factors taken into consideration are 
performance status, comorbidity with renal function 
(not absolute contraindication),69 and patient prefert
ence. Although there are reports of HDT applied to 
individuals age 70 years or even older,70 we suggest that 
the suitable age is younger than 55 years in Taiwan and 
this may be true in other developing countries as well 
where transplant availability and health expense are 
limited. Conversely, different studies have reported that 
the combination of conventional and new drugs can int
duce 70% to 90% PR and 30% to 40% CR. Thus, new 
prospective trials are required to compare new drugs 
plus conventional chemotherapy versus new drugs plus 
HDT/ASCT.
The high early mortality rate (within 100 days) for 
myeloablative allogeneic transplant regimens declined 
from 29% to 10% when reduced intensity conditioning 
regimens (allotRIC) were applied.71 Followtup of most 
studies is too short to determine whether exploitation 
of the welltrecognized grafttversustmyeloma effect 
translates to more durable disease control than reportt
ed with autotransplants. The prospective PETHEMA 
(Programa para el Estudio de la Therapeutica en 
Hemopatia Maligna Group) study reported recently 
that allotRIC had higher CR (40% vs 11%, P=.001) 
but higher transplantationtrelated mortality (16% vs 
5%, P=.07). There is no statistical difference in EFS 
and OS between autotransplant versus allotRIC and 
tandem ASCT. Therefore, we should not use allotRIC 
as a standard approach at present.72 After the eligibilt
ity determination and risk stratification, we follow the 
provisional algorithm illustrated in Figure 2. 
Strategies for risk-adapted therapy in newly diag-
nosed multiple myeloma
There is no evidence that early treatment of patients 
with smoldering MM prolongs survival. However, 
clinical trials are ongoing to determine whether newer 
agents can delay progression.73 
Induction therapy
It is now expected that all patients with MM will have 
responsive disease with initial therapy and that only a 
small minority will remain refractory. We also have to 
consider response quality, toxicity, ease of administrat
tion and health economics. We select the initial therapy 
according to the eligibility of transplantation.
Initial therapy in patients eligible for transplantation
VAD was used for many years as pretransplantation int
duction.19 It is a poorly tolerated regimen and had about 
60% response rate with low CR (13%).74 Therefore, 
VAD is no longer recommended in the United States 
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since the introduction of newer regimens. One of these 
regimens is lenalidomide with lowtdose dexamethat
sone. In a phase 2 trial conducted at the Mayo Clinic, 
91% of patients with newly diagnosed MM achieved 
an objective response, including VGPR in 56%.75 
ECOG (Eastern Cooperative Oncology Group) ret
cently reported preliminary findings of a randomized 
trial testing lenalidomide with hight(RD) or lowt(Rd) 
dose dexamethasone. It showed significantly better OS 
and safety with lowtdose dexamethasone.76 The results 
were updated in the 2008 ASCO (American Society 
of Clinical Oncology) meeting: The 2tyear OS was 
87% (Rd) vs 75% (RD) mainly due to a toxicity dift
ference (30% vs 50%).77 Three recent reports indicate 
a decrease in CDt34 positive cells collected with the 
induction regimen containing lenalidomide. Therefore, 
early harvesting and/or use cyclophosphamide with 
GtCSF is recommended.78 More data are needed for 
universal recommendation of this induction regimen, 
particularly where lenalidomide is not available, such 
as in Taiwan.
The alternative regimen is thalidomide combined 
with dexamethasone (Thal/Dex). In an ECOG rant
domized trial, the best response within 4 cycles was 
significantly higher with Thal/Dex compared with 
dexamethasone alone (63% vs 41%, P=.002).79 The 
other multicenter trial confirmed the result as well.80 If 
doxorubicin is added (TAD), the OR rate is increased 
to 80%.81 These regimens do not affect stemtcell colt
lection or granulocyte and platelet recovery postttranst
plantation.78 Other nonalkylator based regimens can 
also be considered for induction such as bortemzomibt
containing regimens.32,33
Initial therapy in patients ineligible for transplantation 
Patients who are not transplant candidates are treated 
with a standard alkylating agent. A large metatanalysis 
in 1998 showed that the M2 protocol has a higher ret
sponse rate compared to MP, but there is no significant 
difference in response duration and OS (2t3 years).82 
The most commonly used regimen now is melphalan, 
prednisone and thalidomide (MPT). Facon et al rant
domized 447 patients (age 65t75 years) to MP, MPT 
or tandem ASCT with reducedtdose melphalan (100 
mg/m2). A significantly higher response and PFS 
were observed with MPT compared with either MP 
or ASCT groups. The trial demonstrated a significant 
survival advantage with MPT (median OS not reached 
at 52 months, 33 months, and 38 months, respectivet
ly (P<.001).83 Other studies from Palumbo et al and 
Hulin et al also confirmed the superiority of MPT 
over MP.84,85 MPT continues to show a better OR and 
Figure 2. Provisional algorithm for the current approach to the treatment of newly 
diagnosed multiple myeloma Cr indicates complete response; VgPr: very good 
partial response; rev/dex: revlimid (lenalidomide)/ dexamethasone; MPT: melphalan, 
prednisone, thalidomide; MPV: melphalan, prednisone, velcade (bortezomib); MPr: 
melphalan, prednisone, lenalidomide; VTd: velcade, thalidomide, dexamethasone; Thal/
Pred: thalidomide/prednisone.
PFS in elderly patients than MP does, as reflected in 
a recent update by Palumbo et al. However, there was 
no OS advantage from this Italian trial (probable more 
effective salvage in the MP arm).86
The alternative regimen is melphalan, prednisone 
and lenalidomide (MPR). Palumbo et al tested MPR 
in 54 newly diagnosed MM cases older than 65 years. 
At the maximum tolerated dose, the OR rate was 81%, 
with 48% of patients achieving at least VGPR or bett
ter, and 24% of patients achieving CR.87 A trial comt
paring MPT is underway by ECOG.
Consolidation treatment
Consolidation of the initial gains in disease control 
with induction has traditionally used HDT support 
with ASCT. The impact has been demonstrated using 
a conditioning regimen with melphalan alone without 
total body irradiation.65,88 Double transplantation can 
be proposed to patients failing to achieve a VGPR aft
ter a first ASCT,64,72 ideally as a part of a clinical trial. 
A consensus is emerging among myeloma investigators 
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that CR is an important early objective toward achievt
ing durable disease control. 
Maintenance treatment
Observation is still the standard following consolidat
tion. Maintenance treatment has no role in the MP 
period.89,90 It would seem reasonable to engage in a 
maintenance strategy for individuals at high risk or with 
persistent disease. A recent report from Abdelkefi et al 
showed that 6 months of maintenance therapy with 
thalidomide is superior to tandem transplantation (3 
year OS: 85% vs 65%, P=.04).91 Investigations are ont
going with new agents, but the jury is still out.92
Treatment for high-risk groups
Several large studies have shown that patients defined 
as at hightrisk genetically do not have durable responses 
to HDT and may relapse within one year of undergot
ing treatment.88,93 It is possible that a simple induction 
treatment with new novel agents followed by ASCT 
may overcome the adverse prognosis of cytogenetic abt
normalities.35,94 In addition, allogeneic transplantation 
can be considered in very selective patients. Otherwise, 
bortezomibtcontaining regimens can replace transplant
tation as consolidation treatment.35 These regimens 
also showed better longtterm outcome for hightrisk 
disease in patients who were not candidates for transt
plantation.94 This is a major step forward for hightrisk 
patients. Bortezomib with or without dexamethasone 
is highly effective in patients with renal insufficiency, int
cluding patients on dialysis, and does not require dose 
adjustment.95,96
Clinical status of multiple myeloma in Taiwan
The incidence of MM is lowest among the Chinese and 
Japanese, intermediate among Caucasians in America 
and Europe, and highest among AfricantAmericans 
in the USA.97 Recent epidemiological data on MM in 
Taiwan indicate it is now the third most common het
matologic malignancy, just behind the nontHodgkin 
lymphoma (NHL) and acute myelogenous leukemia 
(AML) (MM is second in the USA).3 According to 
the Taiwan National Cancer Registry, there were 3602 
MM patients registered between 1979 and 2003. The 
average agetadjusted incidence per 100 000 populat
tion was 0.75. The average incidence in 1979t1983 and 
1999t2003 was 0.36 and 1.21, respectively. The sex dist
tribution with a malettotfemale ratio was 65% to 35%. 
This has decreased gradually (was 3.6:1). The incidence 
increased with age to a peak of 5.2 in those aged 75t79 
years. The agetadjusted mortality accounted for an avert
age 0.59 per 100 000 deaths.3 
According to a study of 526 patients who were dit
agnosed and treated at National Taiwan University 
Hospital (NTUH), the most common presentation 
was bone pain (55%), followed by dyspnea (12%), tumor 
formation (7%), and infection (6%). The most frequent 
complication was pathologic fracture (31%), followed 
by acute renal failure (10%), neuropathy (6%) and 
amyloidosis (2%). The distribution of DurietSalmon 
stage I and II was 41% and IIIA and IIIB was 59%. 
The most common immunoisotype was IgG (48%), 
followed by IgA (24%), lighttchain disease (20%), and 
IgD (3%).3 The relatively higher incidence of IgD myt
eloma in Taiwan had been reported by another series 
(Chang Gung Memorial Hospital), which showed 
an aggressive clinical features, a male predominance, 
a higher frequency of renal failure, a predilection for 
lambdatlight chains, and shortened survival.98 MGUS 
was also studied and found to have a lower incidence in 
Taiwan as compared to a Western series.99 The author 
published a case presentation in 1988100 and a review 
article in 1990.101 Since then, many case reports have 
been published by a number of authors and hospitals, 
but cannot be listed here due to limited space.
Cytogenetics (CG) analysis had been studied ext
tensively for prediction of prognosis. The cytogenetics 
abnormalities of MM patients in Taiwan are similar to 
those noted in Western countries and in China.102,103 
A series of CG and FISH analyses have been reported 
in Taiwan.102 Cytogenetics abnormalities (CA) were 
detected by CG (CG_CA) in 44 (29.3%) of the 150 
patients and by FISH (FISH_CA) in 59 (67%) of the 
88 patients studied. The presence of cytogenetic abt
normalities by either CG_CA or FISH_CA was ast
sociated with a poor prognosis. Patients with CG_CA 
and hyperdiploid chromosomes, always associated 
with several trisomies, had a longer survival compared 
to those with nonthyperdiploid chromosomes. The latt
ter was usually associated with a monosomy 13/partial 
deletion of 13q (D13) and a rearrangement of 14q32. A 
novel recurrent CG_CA, add(19)(p13), was found in 
four patients in this series. They were all males with imt
munoglobulin G/l isotype, extramedullary myeoloma 
at diagnosis and a poor prognosis.
There are no apparent differences in treatment outt
come between MM patients in Taiwan and in other 
countries.3 Of the 446 patients treated with convent
tional chemotherapy, about half of the patients (220) 
received VAD as one of the chemotherapy regimen, 
and 392 were evaluable for response. There were 210 
(54%) patients who responded, including 13 (6%) 
who had CR, 124 (59%) who had PR, and 73 (35%) 
who had a minimal response. The median PFS was 
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19±2.1 months. There were no significant differences 
in treatment response and PFS between patients ages 
≤55 years and ages >55 years (median PFS, 20.0±6.0 
months vs 19.0±2.4 months, P=.622). Patients who 
responded to conventional chemotherapy had a bett
ter OS, 5tyear and 10tyear survival compared to those 
who did not (44 months, 36%, 10% vs 19 months, 15%, 
3% respectively).3 Among 526 patients, 30 patients ret
ceived HDC/ASCT: 29 were younger than 55 years, 
only one was over 55 years of age. 
Thalidomide has been used in Taiwan since 2000 
as the treatment for relapse or refractory myeloma. In 
a phase 2 study comparing thalidomide alone versus 
thalidomide plus interferontalpha in patients with ret
fractory myeloma, single use of thalidomide showed a 
better response and fewer side effects than combined 
therapy.104 Firsttline treatment with a thalidomidet
containing regimen has been used in Taiwan for many 
years, but the results have not been evaluated extent
sively. Bortezomib has been approved as a thirdtline 
treatment for MM since 2007 in Taiwan. However, let
nalidomide is not yet available. The future is bright for 
the treatment of MM, both in Taiwan and the rest of 
the world, as we evaluate rationally based combinations 
of novel agents to achieve prolonged DFS and explore 
the potential road to cure.
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